SecBot SecBot
SECBOTREPLAY Home › Report › ADCT

ADCT · ASH data + Q3 rev $21M

ADC Therapeutics SA · 8-K filed Nov 4, 2026 at 16:00 ET

At the news

MIXEDIMPACT 6/10

8-K filed Nov 4, 2026 at 16:00 ET

ADC Therapeutics announced positive clinical data from multiple ZYNLONTA trials to be presented at ASH 2026, including high response rates in LOTIS-7 (88.7% ORR) and MZL (93% ORR), alongside preliminary Q3 2026 net product revenue of $21M (up from $16M YoY) and a strengthened balance sheet following an $86.6M PIPE and debt refinancing. However, the LOTIS-5 confirmatory trial showed a Grade 5 safety imbalance (13.2% vs 4.6%) that the FDA flagged as a benefit-risk concern, creating regulatory uncertainty for full approval.

  • Preliminary Q3 2026 ZYNLONTA net product revenue of $21M, up from $16M in Q3 2025
  • LOTIS-7 Phase 1b: 88.7% ORR and 75.3% CR in 97 evaluable r/r DLBCL patients at 10.35 months median follow-up
  • Phase 2 MZL IIT: 93% ORR and 74.4% CR in 43 evaluable patients with 90.8% two-year PFS
  • LOTIS-5 Phase 3 met primary PFS endpoint (HR 0.73, p=0.0083) but Grade 5 TEAEs were 13.2% vs 4.6% in control arm

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access